Jan 06, 2022, 09:00 ET
SEOUL, South Korea, Jan. 6, 2022 /PRNewswire/ -- LISCure Biosciences Inc., a leading biotech
focused on microbial-based therapeutics, announced that it has executed a research collaboration
agreement with Mayo Clinic for new drug development for rare liver diseases.
LISCure has been conducting joint research with Mayo Clinic for NASH drugs since 2021, and this
new collaboration is an agreement signed under the leadership of Nicholas F. LaRusso, M.D. and
Steven P. O'Hara, Ph.D., renowned authorities in the field of rare liver diseases.
Under the terms of the agreement, Mayo Clinic and LISCure metabolic disease R&D teams will
collaborate on preclinical and clinical studies for rare liver diseases including primary sclerosing
cholangitis (PSC), a cholestatic liver disease characterized by chronic liver inflammation and the
progressive destruction of bile ducts.
PSC is an orphan disease of which prevalence ranges from 3 to 16 per 100,000. Unfortunately,
apart from liver transplantation, there are no approved drugs targeting the condition in practical
medical use. Mayo Clinic and LISCure research teams recognized the importance of a microbiome-
based therapeutic approach in PSC treatment and decided to jointly research the efficacy and
additional mechanisms of LISCure's drug candidates.
"LB-P8 program is currently in clinical trials based on the promising results from various animal
models of NASH. We aim to expand our pipeline into rare disease through this research
collaboration with Mayo Clinic for PSC," said Hwasup Chin, CEO of LISCure. "Based on this long-
term collaboration, we seek to provide new treatments to patients with rare liver diseases." He
continues, "we have a new drug candidate in preclinical studies for idiopathic pulmonary fibrosis
and expect to enter a clinical trial in 2023."
LISCure plans to initiate phase 2 clinical trial in the US for LB-P8 in 2H 2022.
SOURCE LISCure Biosciences Inc.